Hope for Lung Cancer Patients

Opdivo outperformed the cancer drug Taxotere in clinical trials of advanced and earlier treated lung cancer.

All patients received the treatment as a second line, following one failed platinum-based chemotherapy regimen.

The study looked at the outcomes after a minimum of 36.6 months and noted that overall survival was clearly improved with Opdivo treatment. At three years, 16% of squamous NSCLC patients treated with Opdivo were still alive. Among those who had been treated with Taxotere, that number was 6%.
Learn More

Learn About Immunotherapy